11.A. Workshop: Risk-benefit Assessment of Foods and Diets for a Sustainable Future

被引：0
|
作者：
Pires, Sara
Thomsen, Sofie Theresa
机构：
来源：
EUROPEAN JOURNAL OF PUBLIC HEALTH | 2023年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
ckad160.69
引用
收藏
页数：1
相关论文
共 50 条
  • [41] RISK-BENEFIT ASSESSMENT OF ANESTHETIC AGENTS IN THE PUERPERIUM
    KANTO, J
    DRUG SAFETY, 1991, 6 (04) : 285 - 301
  • [42] Risk-benefit assessment of nimesulide urgently needed
    Reactions Weekly, 2003, 934 (1) : 3 - 3
  • [43] A risk-benefit assessment of irinotecan in solid tumours
    Siu, LL
    Rowinsky, EK
    DRUG SAFETY, 1998, 18 (06) : 395 - 417
  • [44] A Risk-Benefit Assessment of Pharmacological Therapies for Hirsutism
    Enrico Carmina
    Drug Safety, 2001, 24 : 267 - 276
  • [45] Carbapenems in serious infections - A risk-benefit assessment
    Norrby, SR
    DRUG SAFETY, 2000, 22 (03) : 191 - 194
  • [46] RISK-BENEFIT PROBLEMS IN FOOD SAFETY ASSESSMENT
    FRANCIS, FJ
    JOURNAL OF THE CANADIAN DIETETIC ASSOCIATION-REVUE DE L ASSOCIATION CANADIENNE DES DIETETISTES, 1979, 40 (04): : 274 - 279
  • [47] Clinical risk-benefit assessment of dopamine agonists
    Moeller, J. C.
    Eggert, K. M.
    Unger, M.
    Odin, P.
    Chaudhuri, K. R.
    Oertel, W. H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 : 15 - 23
  • [48] A Risk-Benefit Assessment of Corticosteroids in the Management of Croup
    Robert W. Yates
    Iolo J. M. Doull
    Drug Safety, 1997, 16 : 48 - 55
  • [49] A Risk-Benefit Assessment of Octreotide in the Treatment of Acromegaly
    Aart Jan van der Lely
    Wouter W. de Herder
    Steven W. J. Lamberts
    Drug Safety, 1997, 17 : 317 - 324
  • [50] A Risk-Benefit Assessment of HIV Protease Inhibitors
    Graeme J. Moyle
    Brian G. Gazzard
    Drug Safety, 1999, 20 : 299 - 321
12345